Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxymorphone
Drug ID BADD_D01648
Description An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). On June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulation.
Indications and Usage For the treatment of moderate-to-severe pain.
Marketing Status Prescription; Discontinued
ATC Code N02AA11
DrugBank ID DB01192
KEGG ID D08323
MeSH ID D010111
PubChem ID 5284604
TTD Drug ID D02NSF
NDC Product Code 0406-3433
Synonyms Oxymorphone | Oxymorphone Hydrochloride | Oxymorphone HCl | Numorphan | Opana
Chemical Information
Molecular Formula C17H19NO4
CAS Registry Number 76-41-5
SMILES CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tachycardia02.03.02.0070.005750%Not Available
Tension19.06.02.005--Not Available
Thrombocytopenia01.08.01.0020.014376%Not Available
Thrombotic microangiopathy20.01.07.004; 01.01.02.006; 24.01.01.0130.011501%Not Available
Thrombotic thrombocytopenic purpura24.07.06.014; 23.06.01.011; 01.08.01.0050.025877%
Urethral disorder20.07.01.002--Not Available
Urinary hesitation20.02.02.009--Not Available
Urinary retention20.02.02.011--
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Withdrawal syndrome19.07.02.005; 08.06.02.012--Not Available
Mental status changes19.07.01.0010.005750%Not Available
Brain oedema17.07.02.003; 12.01.10.0100.001500%
Sticky skin23.03.03.019--Not Available
Ureteral spasm20.06.01.002--Not Available
Transaminases increased13.03.01.0150.005750%Not Available
Cancer pain16.32.03.004--Not Available
Troponin increased13.04.01.0040.008626%Not Available
Angiopathy24.03.02.007--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Cardiac disorder02.01.01.003--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages